Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IMP004
MIFTS: 48

Impetigo

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Impetigo

About this section

MalaCards integrated aliases for Impetigo:

Name: Impetigo 12 73 42 44 15 62 17 70 32

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8504
ICD9CM 34 684
MeSH 44 D007169
NCIt 50 C99088
SNOMED-CT 67 156319000
ICD10 32 L01 L01.0
UMLS 70 C0021099
Sources

Summaries for Impetigo

About this section
MedlinePlus : 42 Impetigo is a skin infection caused by bacteria. It is usually caused by staphylococcal (staph) bacteria, but it can also be caused by streptococcal (strep) bacteria. It is most common in children between the ages of two and six. It usually starts when bacteria get into a break in the skin, such as a cut, scratch, or insect bite. Symptoms start with red or pimple-like sores surrounded by red skin. These sores can be anywhere, but usually they occur on your face, arms and legs. The sores fill with pus, then break open after a few days and form a thick crust. They are often itchy, but scratching them can spread the sores. Impetigo can spread by contact with sores or nasal discharge from an infected person. You can treat impetigo with antibiotics.

MalaCards based summary : Impetigo is related to impetigo herpetiformis and bullous impetigo, and has symptoms including fever, pruritus and exanthema. An important gene associated with Impetigo is DSG1 (Desmoglein 1), and among its related pathways/superpathways are Defensins and Keratinization. The drugs Retapamulin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and neutrophil, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A pyoderma consisting of three forms of skin lesions having either a thick, adherent, recurrent, dirty yellow crust with an erythematous margin (common or superficial impetigo) or lessions which are superficial, thin-walled, and bullous as found in bullous impetigo. The lesions in bullous (staphylococcal) impetigo, which are always caused by S aureus, are superficial, thin-walled, and bullous.

PubMed Health : 62 About impetigo: Impetigo is an itchy and sometimes painful infection of the outer layers of skin that is especially common in young children. It is caused by bacteria and is highly contagious. For that reason, children who have impetigo are not allowed to return to school or day care until they are no longer contagious – about 24 hours after the start of treatment with antibiotics. Without treatment, it can remain contagious for several weeks.

Wikipedia : 73 Impetigo is a bacterial infection that involves the superficial skin. The most common presentation is... more...

Sources

Related Diseases for Impetigo

About this section

Diseases related to Impetigo via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Related Disease Score Top Affiliating Genes
1 impetigo herpetiformis 32.4 SERPINB1 PRTN3 PI3 IL36RN ELANE
2 bullous impetigo 32.1 IL6 EDNRB EDNRA DSG3 DSG1 CALCA
3 pustular psoriasis 32.0 PI3 IL36RN ELANE
4 ecthyma 31.9 MYOM2 DSG1
5 exanthem 30.5 PRTN3 IL6 CCR6
6 streptococcal toxic-shock syndrome 30.4 MYOM2 IL6
7 pemphigus vegetans 30.3 DSG1 DSC3
8 pemphigus foliaceus 30.3 DSG3 DSG2 DSG1
9 erysipelas 30.3 PI3 MYOM2 IL6 ELANE CALCA
10 toxic shock syndrome 30.0 MYOM2 IL6 EDNRA
11 bacterial infectious disease 30.0 IL6 ELANE CCR6 CAMP
12 allergic contact dermatitis 29.9 PI3 IL6 CCR6 CALCA
13 syphilis 29.9 PRTN3 IL6 CCR6
14 pyoderma 29.9 MYOM2 IL36RN EDNRB DSG3 DSG1 CCR6
15 cellulitis 29.9 MYOM2 IL6 CCR6 CAMP
16 psoriasis 29.9 PI3 IL6 IL36RN ELANE CCR6 CAMP
17 pyomyositis 29.7 TST MYOM2 EDNRB
18 scarlet fever 29.7 TST MYOM2 EDNRB EDNRA
19 osteomyelitis 29.7 PPP3CA IL6 CALCA
20 pemphigus 29.6 IL6 DSG4 DSG3 DSG2 DSG1 DSC3
21 iga pemphigus 29.5 DSG3 DSG1 DSC3 DSC1
22 disease by infectious agent 29.4 PRTN3 IL6 CCR6 CAMP
23 rosacea 29.4 IL6 CCR6 CAMP
24 acute cystitis 29.4 IL6 CCR6 CAMP
25 connective tissue disease 29.4 IL6 EDNRB EDNRA CCR6 CALCA
26 ritter's disease 28.8 TST EDNRB EDNRA DSG4 DSG3 DSG2
27 pemphigus vulgaris, familial 28.4 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
28 skin disease 27.9 PRTN3 PI3 IL6 IL36RN DSG4 DSG3
29 prolidase deficiency 10.9
30 acute proliferative glomerulonephritis 10.9
31 recessive dystrophic epidermolysis bullosa-generalized other 10.9
32 dermatitis 10.5
33 scabies 10.4
34 herpetiform pemphigus 10.4 DSG3 DSG1
35 tinea imbricata 10.4 DSG3 DSG1
36 pseudomembranous conjunctivitis 10.4 DSG3 DSG1
37 pustulosis of palm and sole 10.4
38 glomerulonephritis 10.4
39 osteosclerotic myeloma 10.3 MYOM2 IL6
40 acute diffuse nephritis 10.3 MYOM2 DSG1
41 indolent plasma cell myeloma 10.3 MYOM2 IL6
42 deep keratitis 10.3 PRTN3 PI3
43 engraftment syndrome 10.3 PI3 CALCA
44 pulmonary hemosiderosis 10.3 PRTN3 IL36RN
45 dermatitis, atopic 10.3
46 tracheitis 10.3 SERPINB1 IL6
47 gorham's disease 10.3 IL6 CALCA
48 pulmonary arterial hypertension associated with connective tissue disease 10.3 EDNRB EDNRA
49 glomeruloid hemangioma 10.3 MYOM2 IL6
50 lichen planus 10.3 IL6 DSG3 DSG1

Comorbidity relations with Impetigo via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Impetigo:



Diseases related to Impetigo
Sources

Symptoms & Phenotypes for Impetigo

About this section

UMLS symptoms related to Impetigo:


fever; pruritus; exanthema

MGI Mouse Phenotypes related to Impetigo:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CAMP CCR6 DSG3 DSG4 EDNRA EDNRB
2 immune system MP:0005387 10.03 CAMP CCR6 DSC1 DSG2 DSG3 DSG4
3 integument MP:0010771 9.73 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4
4 vision/eye MP:0005391 9.32 CAMP DSC1 DSC3 DSG1 DSG2 DSG3
Sources

Drugs & Therapeutics for Impetigo

About this section

PubMed Health treatment related to Impetigo: 62

As long as impetigo doesn't spread beyond a small patch of skin , disinfectant solutions or creams are often recommended. But it isn't clear whether they work. Antibiotic creams have proven effective. Antibiotics that are swallowed (oral antibiotics ) are usually only prescribed if a child has impetigo on a large area of skin or if several parts of their body are affected. Antibiotic tablets are more likely to have side effects than antibiotic creams. For instance, they may cause gastrointestinal (stomach and bowel ) problems. Good hygiene is the key to avoiding infection , especially washing hands frequently, not sharing towels, and washing worn clothing at 60°C (140°F) or higher. It's a good idea to keep the child’s fingernails trimmed very short so they can't scratch themselves as much.

Drugs for Impetigo (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Retapamulin Approved Phase 4 224452-66-8 6918462
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
4
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
5
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
6 Antiparasitic Agents Phase 4
7 Anti-Bacterial Agents Phase 4
8 Anti-Infective Agents Phase 4
9
Mupirocin Approved, Investigational, Vet_approved Phase 3 12650-69-0 446596
10
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
11
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
12
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 3 14838-15-4 26934
13 Respiratory System Agents Phase 2, Phase 3
14 Terpin Phase 2, Phase 3
15 Expectorants Phase 2, Phase 3
16 Antibiotics, Antitubercular Phase 3
17 methicillin Phase 3
18 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
19
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
20 Papaya Approved Phase 1
21
Albendazole Approved, Vet_approved 54965-21-8 2082
22
Diethylcarbamazine Approved, Investigational, Vet_approved 90-89-1 3052
23 Dermatologic Agents
24 Vaccines
25 Liver Extracts

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
2 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Completed NCT01126268 Phase 4 Retapamulin (Altabax)
3 Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology Completed NCT02775617 Phase 4 Ivermectin;Azithromycin;Permethrin
4 A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients Terminated NCT00986856 Phase 4 Fucidin® cream
5 A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo. Unknown status NCT01611909 Phase 2, Phase 3 p-menthane-3,8-diol oil
6 An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo Completed NCT00133874 Phase 3 SB-275833 ointment, 1%
7 A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo. Completed NCT00133848 Phase 3 SB-275833 ointment, 1%
8 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00852540 Phase 3 Retpamulin Ointment, 1%;Linezolid
9 A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo Completed NCT01670032 Phase 2, Phase 3 Experimental: CD07223 1.5 % Topical Gel BID;Experimental: CD07223 1.5% Topical Gel TID;Placebo Comparator: CD07223 vehicle gel BID;Placebo Comparator: CD07223 vehicle gel TID
10 A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo Completed NCT02090764 Phase 3 Ozenoxacin;Placebo
11 A Phase III 3 Arms, Multicenter, Randomised, Investigator-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo Completed NCT01397461 Phase 3 ozenoxacin placebo;retapamulin 1% ointment;ozenoxacin 1% cream
12 Ph-III Randomized, Multicentric, Controlled , Non-inferiority Trial to Evaluate the Safety and Efficacy of Mupirocin Gel 20 mg/g Versus Mupirocin Ointment 20 mg/g and Placebo in the Treatment of Impetigo in Paediatric Population Completed NCT04287777 Phase 3 Mupirocin gel;Mupirocin ointment;Placebo
13 A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo Completed NCT01171326 Phase 2 Topical Minocycline Foam FXFM244
14 A Phase II, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 (1 % and 2 %) Versus Placebo in Impetigo Completed NCT01803035 Phase 2 LTX-109 1 %;LTX-109 2 %;Placebo gel
15 Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) Completed NCT00626795 Phase 2 TD1414 2% cream;TD1414 2% cream;Bactroban® (mupirocin) 2% cream
16 Randomized, Double-Blind, Vehicle Controlled, Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of Topical ATx201 GEL (2% and 4%) in Outpatients With Impetigo Completed NCT03429595 Phase 2 ATx201
17 A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo Completed NCT01367314 Phase 2 NVC-422
18 The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo Completed NCT00758862 Phase 2 2% TD1414 Cream
19 The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT01943136 Phase 1 papaya 1% extract ointment;mupirocin 2% ointment
20 Tele-dermatology of Skin Cancer: a Randomized Trial Comparing Remote Assessment With Conventional Visits in a Cohort of Local Health Authority Employees in the Province of Bergamo (the Shoot the Mole Study) Completed NCT02902822
21 Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union Completed NCT01153828 Retapamulin;Co-prescription of retapamulin and topical mupirocin;Co-prescription of retapamulin and topical fusidic acid
22 Epidemiological Surveillance in India of Group A Streptococcal Infections Including Pharyngitis and Impetigo Supported by Indo-US Vaccine Action Program Completed NCT00342199
23 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
24 East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities Completed NCT00884728

Search NIH Clinical Center for Impetigo

Cochrane evidence based reviews: impetigo

Sources

Genetic Tests for Impetigo

About this section
Sources

Anatomical Context for Impetigo

About this section

MalaCards organs/tissues related to Impetigo:

40
Skin, Liver, Neutrophil, Spinal Cord, Thyroid, T Cells, B Cells
Sources

Publications for Impetigo

About this section

Articles related to Impetigo:

(show top 50) (show all 1560)
# Title Authors PMID Year
1
Community perspectives on scabies, impetigo and mass drug administration in Fiji: A qualitative study. 42 61
33275592 2020
2
Out-of-season increase of puerperal fever with group A Streptococcus infection: a case-control study, Netherlands, July to August 2018. 61 42
33034283 2020
3
Estimation of the force of infection and infectious period of skin sores in remote Australian communities using interval-censored data. 61 42
33017395 2020
4
Disseminated bullous impetigo in atopic dermatitis ('eczema staphylococcatum'). 61
33217078 2021
5
Disseminated gonococcal infection in a Japanese man with complement 7 deficiency with compound heterozygous variants: A case report. 61
33787610 2021
6
[Palmoplantar dermatoses in children]. 61
33580281 2021
7
Mask-induced Koebner phenomenon and its clinical phenotypes: A multicenter, real-life study focusing on 873 dermatological consultations during COVID-19 pandemics. 61
33527560 2021
8
Prevalence of scabies and impetigo in school-age children in Timor-Leste. 61
33722285 2021
9
A comparative review of current topical antibiotics for impetigo. 61
33726585 2021
10
Impetigo as an adverse effect of topical 5% imiquimod treatment for viral warts. 61
33660286 2021
11
The economic and health burdens of diseases caused by group A Streptococcus in New Zealand. 61
33278622 2021
12
Bullous impetigo mimicking epidermolysis bullosa. 61
33666050 2021
13
Defining the need for public health control of scabies in Solomon Islands. 61
33617544 2021
14
Efficacy and safety of treatment with anti-tumor necrosis factor-α drugs for severe impetigo herpetiformis. 61
33035362 2021
15
A Structured Approach to Skin and Soft Tissue Infections (SSTIs) in an Ambulatory Setting. 61
33535501 2021
16
Echtyma gangrenosum caused by coinfection with group A Streptococcus and Staphylococcus aureus: an emerging etiology? Case reports and literature review. 61
31210583 2021
17
Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: A case report and review of published cases. 61
33599999 2021
18
Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo. 61
33538559 2021
19
Problematic Purpura. 61
33777561 2021
20
A Case of Bullous Rash Apparently Triggered by Meningococcal and Rotavirus Vaccines in an Infant: Focus on Infantile Bullous Pemphigoid. 61
33672215 2021
21
Health Disparities among Australia's Remote-Dwelling Aboriginal People: A Report from 2020. 61
33241298 2021
22
The Botfly, A Tropical Menace: A Distinctive Myiasis Caused by Dermatobia hominis. 61
32797356 2021
23
Streptococcus pyogenes Is Associated with Idiopathic Cutaneous Ulcers in Children on a Yaws-Endemic Island. 61
33436440 2021
24
Natural history of non-bullous impetigo: a systematic review of time to resolution or improvement without antibiotic treatment. 61
33558328 2021
25
Carpet beetle dermatitis mimicking bullous impetigo. 61
33247445 2021
26
Hospital admissions for skin and soft tissue infections in a population with endemic scabies: A prospective study in Fiji, 2018-2019. 61
33296378 2020
27
Intolerable Burden of Impetigo in Endemic Settings: A Review of the Current State of Play and Future Directions for Alternative Treatments. 61
33333955 2020
28
Therapeutic applications of lysostaphin against Staphylococcus aureus. 61
33382154 2020
29
A scabies outbreak in the North East Region of Ghana: The necessity for prompt intervention. 61
33351803 2020
30
The prevalence of scabies in Monrovia, Liberia: A population-based survey. 61
33284821 2020
31
Epidemiological analysis of Group A Streptococcus infections in a hospital in Beijing, China. 61
32676802 2020
32
Cutaneous adverse-events in patients treated with Ibrutinib. 61
32790083 2020
33
Home remedies in different pediatric dermatoses: An observational study. 61
32761779 2020
34
Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus. 61
33202815 2020
35
Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects. 61
32531105 2020
36
[PUSTULAR PSORIASIS DURING PREGNANCY: WHEN IS THE RIGHT TIME TO DELIVER?] 61
33210847 2020
37
Dermatologic manifestations in pediatric patients after liver and HSCT: A 20-year retrospective cohort study. 61
33142028 2020
38
Impetigo. 61
33105179 2020
39
Anetodermic lesions following pityriasis rosea and impetigo. 61
30229641 2020
40
Impetigo Animal Models: A Review of Their Feasibility and Clinical Utility for Therapeutic Appraisal of Investigational Drug Candidates. 61
33066386 2020
41
Unique surface structures of community-associated methicillin-resistant Staphylococcus aureus ST8/SCCmecIVl. 61
33060039 2020
42
Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study). 61
32868360 2020
43
Trichloroacetic acid peel complicated with impetigo contagious infection. 61
33158320 2020
44
Kampo medicines suppress the production of exfoliative toxins causing impetigo in Staphylococcus aureus. 61
32415796 2020
45
A case of goggle-mask-related impetigo at the time of the COVID-19 pandemic. 61
32436604 2020
46
A case of impetigo herpetiformis in which termination of pregnancy was required. 61
32643981 2020
47
Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case. 61
32406109 2020
48
Using the MCRISP Network for Surveillance of Pediatric Exanthema in Child Care Centers. 61
32693853 2020
49
Preparation and characterization of a novel thermosensitive and bioadhesive cephalexin nanohydrogel: a promising platform for topical antibacterial delivery. 61
32441175 2020
50
Looking for NTDs in the skin; an entry door for offering patient centered holistic care. 61
32614791 2020
Sources

Variations for Impetigo

About this section
Sources

Expression for Impetigo

About this section
Search GEO for disease gene expression data for Impetigo.
Sources

Pathways for Impetigo

About this section

Pathways related to Impetigo according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Defensins 65
Show member pathways
 11.69 PRTN3 PI3 ELANE CCR6 CAMP
2
Keratinization 65
Show member pathways
 11.62 PI3 DSG4 DSG3 DSG2 DSG1 DSC3
3
C-MYB transcription factor network 1
11.32 PRTN3 PPP3CA ELANE
4
Endothelin Pathways 1
10.86 EDNRB EDNRA CALCA
Sources

GO Terms for Impetigo

About this section

Cellular components related to Impetigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 SERPINB1 PRTN3 PI3 IL6 IL36RN ELANE
2 extracellular space GO:0005615 9.97 TST SERPINB1 PRTN3 PI3 IL6 IL36RN
3 cell junction GO:0030054 9.8 PPP3CA DSG4 DSG3 DSG2 DSG1 DSC3
4 cell-cell junction GO:0005911 9.63 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
5 desmosome GO:0030057 9.43 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
6 cornified envelope GO:0001533 9.17 PI3 DSG4 DSG3 DSG2 DSG1 DSC3

Biological processes related to Impetigo according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.91 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
2 neutrophil degranulation GO:0043312 9.85 SERPINB1 PRTN3 ELANE DSG1 DSC1 CAMP
3 cellular response to lipopolysaccharide GO:0071222 9.76 IL6 IL36RN EDNRB CAMP
4 keratinization GO:0031424 9.73 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
5 calcium-mediated signaling GO:0019722 9.71 PPP3CA EDNRB CCR6
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.71 EDNRB EDNRA CCR6 CALCA
7 regulation of blood pressure GO:0008217 9.69 EDNRB EDNRA CALCA
8 positive regulation of interleukin-8 production GO:0032757 9.65 IL6 ELANE CALCA
9 cell-cell adhesion GO:0098609 9.63 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
10 antimicrobial humoral response GO:0019730 9.62 PRTN3 PI3 ELANE CAMP
11 enteric nervous system development GO:0048484 9.56 EDNRB EDNRA
12 leukocyte migration involved in inflammatory response GO:0002523 9.55 ELANE CCR6
13 negative regulation of chemokine production GO:0032682 9.52 IL6 ELANE
14 endothelin receptor signaling pathway GO:0086100 9.49 EDNRB EDNRA
15 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007156 9.43 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
16 cornification GO:0070268 9.17 PI3 DSG4 DSG3 DSG2 DSG1 DSC3

Molecular functions related to Impetigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.17 PPP3CA DSG4 DSG3 DSG2 DSG1 DSC3
2 gamma-catenin binding GO:0045295 9.16 DSG1 DSC3
3 endothelin receptor activity GO:0004962 8.96 EDNRB EDNRA
Sources

Sources for Impetigo

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....